Jul 3 |
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
|
Jul 3 |
5 FDA decisions to watch in the third quarter
|
Jul 2 |
Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune
|
Jun 12 |
ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
|
Jun 3 |
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
|
May 30 |
Adaptimmune, Galapagos to collaborate on uza-cel T-cell therapy
|
May 30 |
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
|
May 15 |
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
|
May 15 |
Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M
|
May 15 |
Adaptimmune Therapeutics gets $125M in financing from Hercules Capital
|